Dublin, Feb. 21, 2017 -- Research and Markets has announced the addition of Jain PharmaBiotech's new report "Biochips and Microarrays - Technologies, Markets and Companies" to their offering.
This report is an analysis of biochip/microarray markets based on technologies and applications. The report starts with a description of technologies as a basis for estimation of markets. Technologies include array comparative genomic hybridization (CGH), copy number variation (CNV), DNA methylation, ChIP-Chip, RNA splice variants, and microRNA. Separate chapters are devoted to protein biochips/microarrays, microfluidics and nanobiotechnology-based nano-arrays.
Various applications of biochips and microarrays are described throughout the report. Areas of application such as point-of-care, genetic screening, cancer, and diagnosis of infections are included. Separate chapters are devoted to applications in drug discovery and development as well as personalized medicine
The report provides current share of each segment: market size in 2016 and projected value for the years 2021 and 2026. Gene expression has the largest share and is an established market. Share of microarray technologies in other areas will grow with the maximum growth in RNA splice variants followed by epigenetics. The growth in protein microarrays is somewhat less, partly because it is more mature than the other submarkets and has already shown considerable growth in the past. Impact of next generation sequencing on segments of microarray markets is identified. Customer requirements and unmet needs are described. Markets are also analyzed according to geographical areas.
Brief profiles of companies involved in biochip/microarray technologies are provided. Currently selected 92 companies are included along with listing of 120 collaborations between companies. The text is supplemented by 21 tables, 11 figures and 140 references to literature.
Key Topics Covered:
Executive Summary
1. Introduction
2. Biochip and Microarray Technologies
3. Microfluidics-based Biochips and Microarrays
4. Protein Biochips
5. Nanobiotechnology-based Biochips & Microarrays
6. Biochips & Microarrays for Epigenetics
7. Applications of Microarrays in Drug Discovery & Development
8. Biochips for Biomarkers, Molecular Diagnostics & Personalized
9. Markets
10. Companies
11. References
For more information about this report visit http://www.researchandmarkets.com/research/d2np4r/biochips_and
Source: Jain PharmaBiotech
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Biotechnology


Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
Washington Post Publisher Will Lewis Steps Down After Layoffs
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment
Instagram Outage Disrupts Thousands of U.S. Users
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 



